Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name TP53 mutant
Gene Variant Detail

TP53 mutant (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03567642 Phase I Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers Active, not recruiting USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT03945721 Phase I Niraparib A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients (UNITY) Active, not recruiting USA 0
NCT04783415 Phase II Acalabrutinib + Ublituximab + Umbralisib Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma Active, not recruiting USA 0
NCT03732352 Phase II Osimertinib 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma Completed USA 0
NCT03844815 Phase I Decitabine + Venetoclax Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03047993 Phase Ib/II Azacitidine + Telaglenastat Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed USA 0
NCT04659616 Phase I Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT04285567 Phase III Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO) Active, not recruiting USA | ITA | FRA | ESP | AUS 0
NCT04190550 Phase I Cytarabine + Idarubicin + KRT-232 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia Active, not recruiting USA 0
NCT02343172 Phase Ib/II Ribociclib + Siremadlin Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma Completed FRA | ESP | DEU | CAN 2
NCT06511882 Phase II Decitabine + Venetoclax Azacitidine + Venetoclax Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD Recruiting USA 0
NCT05554393 Phase II Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Recruiting USA | CAN 1
NCT02098343 Phase Ib/II Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 Completed USA | SWE | NLD | GBR | FRA | ESP | DEU | BEL 0
NCT06366347 Phase II Pembrolizumab Abemaciclib + Letrozole ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab Recruiting USA 0
NCT04592237 Phase II Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer Active, not recruiting USA 0
NCT02007044 Phase II Ibrutinib Ibrutinib + Rituximab Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT02576444 Phase II Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib OLAParib COmbinations (OLAPCO) Terminated USA 0
NCT03661307 Phase Ib/II Decitabine + Quizartinib + Venetoclax Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03634228 Phase Ib/II Cytarabine + Milademetan Cytarabine + Milademetan + Venetoclax Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia Terminated USA 0
NCT04169737 Phase II Acalabrutinib + Obinutuzumab + Venetoclax Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Recruiting USA 0
NCT02301156 Phase III Ibrutinib + Ublituximab Ibrutinib Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed USA | ISR 0
NCT01357161 Phase II Carboplatin Adavosertib Paclitaxel A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed 0
NCT05275439 Phase I Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML Active, not recruiting USA | GBR | CAN 0
NCT05008055 Phase II Capivasertib Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) Active, not recruiting USA | GBR | FRA | ESP | DNK | CAN 1
NCT03365661 Phase II Nogapendekin alfa inbakicept QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML Withdrawn USA 0
NCT05512377 Phase II BI 907828 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Recruiting USA | GBR | FRA | ESP | DEU | CHE | BEL | AUT | AUS 7
NCT03462719 Phase III Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW) Active, not recruiting USA | TUR | SWE | POL | NLD | ISR | GBR | FRA | ESP | DNK | CZE | CAN | BEL 1
NCT05495464 Phase I Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma Recruiting USA 0
NCT05180695 Phase Ib/II Pazopanib + Siremadlin HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC) Recruiting FRA 0
NCT01027416 Phase I Tamoxifen Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients Completed USA 0
NCT04113616 Phase Ib/II KRT-232 Decitabine + KRT-232 Cytarabine + KRT-232 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) Terminated USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | BEL | AUS 1
NCT03734198 Phase II Daratumumab + Ibrutinib Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) Active, not recruiting FRA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT05431582 Phase I Bevacizumab + Pembrolizumab + ZN-c3 Bevacizumab + ZN-c3 Phase I Study of ZN-c3 and Bevacizumab +/- Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors Withdrawn 0
NCT03613532 Phase I Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Recruiting USA 0
NCT03063203 Phase II Decitabine Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Terminated USA 0
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated USA 0
NCT05332483 Phase I Megestrol acetate Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer (MA-EEC) Terminated CAN 0
NCT05611931 Phase III Selinexor Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042) Recruiting USA | SVK | ITA | ISR | IRL | HUN | GRC | ESP | DEU | CZE | CAN | BEL | AUS 1
NCT04510584 Phase II Atezolizumab + Bevacizumab Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer Withdrawn CAN 0
NCT03072043 Phase Ib/II APR-246 + Azacitidine Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Completed USA 0
NCT05748171 Phase II Asparaginase + Dexamethasone + Mitoxantrone + Vincristine Sulfate Inotuzumab ozogamicin A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL Recruiting SWE | SVK | POL | NOR | NLD | ITA | ISR | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CHE | BEL | AUT 0
NCT06578624 Phase Ib/II SA53-OS Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors Not yet recruiting USA 0
NCT02042989 Phase I Ixazomib + Vorinostat MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies Completed USA 0
NCT03931291 Phase II APR-246 + Azacitidine APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant Completed USA 0
NCT04634877 Phase III Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Active, not recruiting USA | TUR | SWE | POL | NOR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUT | ARG 9
NCT04722172 Phase II Acalabrutinib + Obinutuzumab A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL Active, not recruiting USA 0
NCT06136884 Phase I AO-252 A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors Recruiting USA 0
NCT03449381 Phase I BI 907828 This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) Active, not recruiting USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL 2
NCT05155709 Phase Ib/II Azacitidine + Siremadlin + Venetoclax A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. Completed USA | TUR | ITA | ISR | HUN 2
NCT04708054 Phase II Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Recruiting USA 0
NCT04214860 Phase I APR-246 + Azacitidine + Venetoclax APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies Completed USA 0
NCT04419389 Phase Ib/II Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) Terminated USA 0
NCT05396859 Phase I Decitabine and Cedazuridine + Entrectinib Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia Recruiting USA 0
NCT04402073 Phase II Cisplatin + Lomustine + Vincristine Sulfate Cisplatin + Lomustine + Sonidegib + Vincristine Sulfate Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I) Active, not recruiting NLD | ITA | FRA | ESP | DEU | CHE | AUT | AUS 0
NCT01339871 Phase I Vorinostat Pazopanib Phase I Study of Pazopanib and Vorinostat Completed USA 0
NCT04010968 Phase II Ibrutinib + Venetoclax Cyclophosphamide + Fludarabine + Rituximab Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC) Active, not recruiting FRA 0
NCT03668340 Phase II Adavosertib AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Active, not recruiting USA 0
NCT04493138 Phase Ib/II Azacitidine + Quizartinib Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Recruiting USA 0
NCT06107868 Phase I Carboplatin + Paclitaxel + RP-6306 Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (GyneRep) Active, not recruiting CAN 0
NCT06152809 Phase I Aldesleukin + CIML-NK cells + Venetoclax CIML NK Cells With Venetoclax for AML Active, not recruiting USA 0
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting USA 0
NCT03128879 Phase II Acalabrutinib + Venetoclax Ibrutinib + Venetoclax Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL Recruiting USA 0
NCT04660045 Phase II Acalabrutinib Early Intervention With Acalabrutinib in Patients With High Risk CLL Withdrawn USA 0
NCT03836261 Phase III Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY) Active, not recruiting USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG 6
NCT04435691 Phase Ib/II Azacitidine + Hu5F9-G4 + Venetoclax Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04293094 Phase I AMG 650 Study of AMG 650 in Adult Participants With Advanced Solid Tumors Completed USA | ITA | ESP | CAN | BEL | AUS 1
NCT05622058 Phase I ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer Terminated USA | BGR 2
NCT03383575 Phase II Azacitidine + Enasidenib Enasidenib Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Recruiting USA 0
NCT04734990 Phase Ib/II Azacitidine + Seclidemstat Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT03787602 Phase Ib/II Avelumab + KRT-232 KRT-232 Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | BRA | AUS 1
NCT01760525 Phase I CGM097 A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors Completed USA | FRA | DEU | CHE 1
NCT04908228 Phase II Ibrutinib + Obinutuzumab Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL (FIGHT) Recruiting ITA 0
NCT06482684 Phase II Ibrutinib Ibrutinib + Rituximab Bendamustine + Ibrutinib + Rituximab Cyclophosphamide + Doxorubicin + Ibrutinib + Prednisone + Rituximab + Vincristine Sulfate Brexucabtagene autoleucel Cisplatin + Cytarabine + Dexamethasone + Rituximab CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma (CARMAN) Recruiting DEU 0
NCT02275039 Phase I MVAp53 Gemcitabine p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer Completed USA 0
NCT03360721 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed USA 0
NCT05376800 Phase I BI 907828 A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma Recruiting USA | ESP | BEL 0
NCT06058793 Phase III BI 907828 Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Active, not recruiting USA | ITA | GBR | CAN | BRA | BEL | AUS | ARG 1
NCT05156268 Phase II Olaparib + Pembrolizumab A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma Active, not recruiting USA 0
NCT03204188 Phase II Fludarabine + Ibrutinib + Pembrolizumab Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting USA 0
NCT05027867 Phase II KRT-232 KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer Terminated USA | HUN | FRA | ESP | DEU | AUS 1
NCT05218499 Phase II BI 907828 Doxorubicin Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Active, not recruiting USA | SWE | NOR | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BEL | AUS 5
NCT02629809 Phase II Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia Active, not recruiting USA 0
NCT02642042 Phase II Docetaxel + Trametinib Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Active, not recruiting USA 0
NCT05624554 Phase III Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab ARQ 531 A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Recruiting USA | TUR | ROU | POL | LTU | HUN | DNK | BRA | BGR | AUS 11
NCT04388852 Phase I DS-3201b + Ipilimumab DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Recruiting USA 0
NCT04277442 Phase I Decitabine + Nivolumab + Venetoclax Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia Active, not recruiting USA 0
NCT04159155 Phase II Carboplatin + Cisplatin + Paclitaxel Carboplatin + Niraparib + Paclitaxel Carboplatin + Paclitaxel A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP) Recruiting CAN 0
NCT03745716 Phase III APR-246 + Azacitidine Azacitidine APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) Completed USA | FRA 0
NCT06297629 Phase II Decitabine and Cedazuridine A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation Withdrawn USA 0
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Active, not recruiting CAN 0
NCT03932643 Phase I ONC201 ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant Active, not recruiting USA 0
NCT05405309 Phase Ib/II Olaparib + RP-3500 RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL) Terminated USA 0
NCT04485260 Phase Ib/II KRT-232 + Ruxolitinib An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib Unknown status USA | POL | ITA | ISR | FRA | ESP | DEU | BGR | AUS 0
NCT06313437 Phase I Cytarabine + Daunorubicin + Midostaurin + Revumenib Cytarabine + Midostaurin + Revumenib Revumenib in Combination With 7+3 + Midostaurin in AML Not yet recruiting USA 0
NCT03781986 Phase Ib/II Alrizomadlin APG-115 in Salivary Gland Cancer Trial Active, not recruiting USA 0
NCT04022876 Phase I ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Terminated USA | POL | ITA | ESP | DEU 2
NCT04412629 Phase II Cabozantinib Cabozantinib in High Grade Neuroendocrine Neoplasms Recruiting USA 0